On October 29, 2020, Heymach, John; Robichaux, Jacqulyne; Nilsson, Monique; Jones, Philip; Cross, Jason; Theroff, Jay published a patent.Recommanded Product: 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine The title of the patent was Preparation of pyridopyrimidines as inhibitors of tyrosine kinase for the treatment or prevention of diseases. And the patent contained the following:
The invention relates to preparation of pyridopyrimidines(I) as inhibitors of tyrosine kinase which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of diseases, including cancer. Compounds I wherein A1 is C(R1)or N; A2 is C(R2)or N; A3 is C(R3)or N; Ar1 is aryl or heteroaryl; R1 is halo, CN, OR6, etc.; R2 is H, alkyl, alkoxy; R3 is H or alkyl; R6 is alkyl, H, C(=O)alkyl, are claimed. The example compound II was prepared via 10-step synthetic procedure using 6-fluoropyridin-3-amine as starting material (procedure given). Compounds I were evaluated for their biol. activity (data given). Compounds I can be used in treatment or prevention of HER2- and EGFR-mediated diseases. The experimental process involved the reaction of 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine(cas: 175357-98-9).Recommanded Product: 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine
The Article related to enamide pyridopyrimidine preparation tyrosine kinase inhibitor cancer treatment prophylaxis, pyridopyrimidine preparation mutation her2 egfr inhibitor disease treatment prophylaxis and other aspects.Recommanded Product: 4-Chloro-6-fluoropyrido[3,4-d]pyrimidine
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia